Successful Treatment of Refractory Hailey-Hailey Disease with Dupilumab: A Case Report
Main Article Content
Keywords
Hailey-Hailey Disease, Dupilumab, Therapy, Biologic, Benign Familial Pemphigus
Abstract
Hailey-Hailey disease (HHD) is an autosomal dominant blistering dermatosis with incomplete penetrance caused by an ATP2C1 gene mutation. Currently, there is no cure for HHD; however therapeutic options aim to minimize the exacerbating factors and manage patients’ symptoms. A 58-year-old male presented with a 10-year history of biopsy-proven HHD. He was seen consistently over the course of nine years with multiple flares a year consisting of pruritic and painful intertriginous plaques with involvement of the chest, upper arms, and back. His disease was recalcitrant to topicals, oral and topical antibiotics, phototherapy, and systemic corticosteroids. He was started on dupilumab and noticed significant improvement. We present a case of HHD recalcitrant to various modalities of treatment. Our description of rapid improvement with dupilumab suggests a role for Th2 signaling in the pathophysiology of HHD. We propose that dupilumab works for HHD due to the significant skin barrier dysfunction, similar to atopic dermatitis, and consider whether inflammation plays an earlier role in the disease. Although used for an off-label purpose, in this case, further studies should assess the clinical response and safety of patients with recalcitrant HHD treated with dupilumab.
References
2. Micaroni M, Giacchetti G, Plebani R, Xiao GG, Federici L. ATP2C1 gene mutations in Hailey–Hailey disease and possible roles of SPCA1 isoforms in membrane trafficking. Cell Death Dis. 2016;7(6):e2259-e2259. doi:10.1038/cddis.2016.147.
3. Shull GE, Miller ML, Prasad V. Secretory Pathway Stress Responses as Possible Mechanisms of Disease Involving Golgi Ca2+ Pump Dysfunction. Biofactors Oxf Engl. 2011;37(3):150-158. doi:10.1002/biof.141.
4. Rabeni EJ, Cunningham NM. Effective treatment of Hailey-Hailey disease with topical tacrolimus∗. J Am Acad Dermatol. 2002;47(5):797-798. doi:10.1067/mjd.2002.126217.
5. Tchernev G, Cardoso J. Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option. Rev Médica Chile. 2011;139:633-637. doi:10.4067/S0034-98872011000500011.
6. Alzahrani N, Grossman-Kranseler J, Swali R, et al. Hailey–Hailey disease treated with dupilumab: a case series. Br J Dermatol. 2021;185(3):680-682. doi:10.1111/bjd.20475.
7. Alamon-Reig F, Serra-García L, Bosch-Amate X, Riquelme-Mc Loughlin C, Mascaró JM. Dupilumab in Hailey-Hailey disease: A case series. J Eur Acad Dermatol Venereol JEADV. Published online June 23, 2022. doi:10.1111/jdv.18350.
8. Licata G, Buononato D, Calabrese G, et al. A case of Hailey-Hailey disease successfully treated with dupilumab. Int J Dermatol. Published online June 29, 2022. doi:10.1111/ijd.16322.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.